Skip to main content
SpringerLink
Log in

Botulinum Toxin in Treatment of Bladder Pain Syndrome/Interstitial Cystitis

  • Chapter
  • First Online:
Bladder Pain Syndrome – An Evolution

  • 604 Accesses

Abstract

Botulinum toxin (BonTA) exerts its main therapeutic by inhibiting neuro-mediator exocytosis [1]. This was originally seen with acetylcholine hence the first diseases to be treated with BonTA injections where ocular strabismus and other striated muscular conditions [2]. In urologic diseases use of BonTA also started with application to striated muscle. In this case the urethral sphincter was targetd for treatment of sphincter-detrusor dissynergia in spinal cord injury patients [3]. With the rationale of smooth muscle relaxation, intra-vesical injections where approved initially for neurogenic detrusor over activity and later for the idiopathic overactive bladder syndrome. These applications showed great success and presently are mainstays of neurogenic and idiopathic bladder over activity treatment [4–6]. Since both the toxic effects as well as therapeutic effects of BonTA were seen as an efferent neuronal effect it was initially overlooked in the treatment of bladder pain.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schiavo G, Rossetto O, Benfenati F, Poulain B, Montecucco C. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann N Y Acad Sci. 1994;710:65–75.

    Article  CAS  PubMed  Google Scholar 

  2. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17(1):21–5.

    CAS  PubMed  Google Scholar 

  3. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.

    Article  CAS  PubMed  Google Scholar 

  4. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.

    Article  CAS  PubMed  Google Scholar 

  5. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6.

    Article  CAS  PubMed  Google Scholar 

  6. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol. 2004;172(6 Pt 1):2316–20.

    Article  CAS  PubMed  Google Scholar 

  7. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38(2):245–58.

    Article  CAS  PubMed  Google Scholar 

  8. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174(3):977–82. discussion 82-3

    Article  CAS  PubMed  Google Scholar 

  9. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5. discussion 5

    Article  PubMed  Google Scholar 

  10. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49(4):704–9.

    Article  CAS  PubMed  Google Scholar 

  11. Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr Drug Deliv. 2010;7(1):1–4.

    Article  CAS  PubMed  Google Scholar 

  12. Avelino A, Cruz C, Nagy I, Cruz F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience. 2002;109(4):787–98.

    Article  CAS  PubMed  Google Scholar 

  13. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5.

    Article  CAS  PubMed  Google Scholar 

  14. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–61.

    Article  CAS  PubMed  Google Scholar 

  15. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609–14.

    Article  CAS  PubMed  Google Scholar 

  16. Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, et al. Botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int J Urol. 2015;22(9):835–41.

    Article  CAS  PubMed  Google Scholar 

  17. Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013;189(2):548–53.

    Article  CAS  PubMed  Google Scholar 

  18. Kasyan G, Pushkar D. 822 randomized controlled trial for efficacy of botulinum toxin type a in treatment of patients suffering bladder pain syndrome/interstitial cystitis with hunners’ lesions preliminary results. J Urol. 2012;187(4):e335–e6.

    Article  Google Scholar 

  19. Shim SR, Cho YJ, Shin IS, Kim JH. Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(8):1215–27.

    Article  CAS  PubMed  Google Scholar 

  20. Wang J, Wang Q, Wu Q, Chen Y, Wu P. Intravesical botulinum toxin A injections for bladder pain syndrome/interstitial cystitis: a systematic review and meta-analysis of controlled studies. Med Sci Monit. 2016;22:3257–67.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kuo YC, Kuo HC. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis--different mechanisms of action of botox on bladder dysfunction? Toxins (Basel). 2016;8(3):75.

    Article  Google Scholar 

  22. Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014;65(6):1117–24.

    Article  CAS  PubMed  Google Scholar 

  23. Ahmadi H, Montaser-Kouhsari L, Kajbafzadeh A-M. 744 intravesical electromotive botulinum toxin type A administration: preliminary findings for the treatment of children with myelomeningocele and refractory neurogenic detrusor overactivity. J Urol. 2010;183(4):e291.

    Article  Google Scholar 

  24. Stav K, Vinshtok Y, Jeshurun M, Ivgy-May N, Gerassi T, Zisman A. PD20-03 pilot study evaluating safety and feasibility of intravesical instillation of botulinum toxin in hydrogel-based slow release delivery system in PBS/IC patients. J Urol. 2015;193(4):e398.

    Article  Google Scholar 

  25. Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ. Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol. 2017;197(4):982–90.

    Article  CAS  PubMed  Google Scholar 

  26. Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological A. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.

    Article  PubMed  Google Scholar 

  27. Engeler D, Baranowski AP, Borovicka J, Dinis-Oliveira P, Elneil S, Hughes J, et al. EAU guidelines on chronic pelvic pain. Arnhem: EAU Guidelines Office; 2016.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine, Hospital de São João, Porto, Portugal

    Paulo Dinis

Authors
  1. Paulo Dinis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paulo Dinis .

Editor information

Editors and Affiliations

  1. Stanford University School of Medicine, Stanford, California, USA

    Philip M. Hanno

  2. Department of Urology, Herlev Hospital, Herlev, Denmark

    Jørgen Nordling

  3. St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA

    David R. Staskin

  4. Penn Medicine, Perelman School of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA

    Alan J. Wein

  5. Urology, Antwerp University, GGW, Wilrijk, Antwerp, Belgium

    Jean Jacques Wyndaele

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Dinis, P. (2018). Botulinum Toxin in Treatment of Bladder Pain Syndrome/Interstitial Cystitis. In: Hanno, P., Nordling, J., Staskin, D., Wein, A., Wyndaele, J. (eds) Bladder Pain Syndrome – An Evolution. Springer, Cham. https://doi.org/10.1007/978-3-319-61449-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-61449-6_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-61448-9

  • Online ISBN: 978-3-319-61449-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation